JPWO2021110805A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2021110805A5
JPWO2021110805A5 JP2022531534A JP2022531534A JPWO2021110805A5 JP WO2021110805 A5 JPWO2021110805 A5 JP WO2021110805A5 JP 2022531534 A JP2022531534 A JP 2022531534A JP 2022531534 A JP2022531534 A JP 2022531534A JP WO2021110805 A5 JPWO2021110805 A5 JP WO2021110805A5
Authority
JP
Japan
Prior art keywords
isopropylphenyl
pulmonary fibrosis
fibrosis
azetidin
carbamoyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022531534A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023504415A (ja
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2020/084401 external-priority patent/WO2021110805A1/en
Publication of JP2023504415A publication Critical patent/JP2023504415A/ja
Publication of JPWO2021110805A5 publication Critical patent/JPWO2021110805A5/ja
Pending legal-status Critical Current

Links

JP2022531534A 2019-12-04 2020-12-03 線維性疾患の治療に使用するためのアゼチジンlpa1受容体アンタゴニストのピルフェニドン及び/又はニンテダニブとの合剤 Pending JP2023504415A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP2019083757 2019-12-04
EPPCT/EP2019/083757 2019-12-04
PCT/EP2020/084401 WO2021110805A1 (en) 2019-12-04 2020-12-03 Combination of an azetidine lpa1 receptor antagonist with pirfenidone and/or nintedanib for use in the treatment of fibrotic diseases

Publications (2)

Publication Number Publication Date
JP2023504415A JP2023504415A (ja) 2023-02-03
JPWO2021110805A5 true JPWO2021110805A5 (es) 2023-12-12

Family

ID=76221504

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022531534A Pending JP2023504415A (ja) 2019-12-04 2020-12-03 線維性疾患の治療に使用するためのアゼチジンlpa1受容体アンタゴニストのピルフェニドン及び/又はニンテダニブとの合剤

Country Status (13)

Country Link
US (1) US20230000846A1 (es)
EP (1) EP4069227A1 (es)
JP (1) JP2023504415A (es)
KR (1) KR20220109439A (es)
CN (1) CN114761001A (es)
AU (1) AU2020397207A1 (es)
BR (1) BR112022010891A2 (es)
CA (1) CA3160410A1 (es)
CL (1) CL2022001439A1 (es)
IL (1) IL293474A (es)
MX (1) MX2022006736A (es)
TW (1) TW202133844A (es)
WO (1) WO2021110805A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114728168B (zh) 2019-11-15 2024-04-09 吉利德科学公司 三唑氨基甲酸酯吡啶基磺酰胺作为lpa受体拮抗剂及其用途
EP4161936A1 (en) 2020-06-03 2023-04-12 Gilead Sciences, Inc. Lpa receptor antagonists and uses thereof
TWI838626B (zh) 2020-06-03 2024-04-11 美商基利科學股份有限公司 Lpa受體拮抗劑及其用途
EP4337641A1 (en) 2021-05-11 2024-03-20 Gilead Sciences, Inc. Lpa receptor antagonists and uses thereof
AU2022405082A1 (en) 2021-12-08 2024-07-11 Gilead Sciences, Inc. Lpa receptor antagonists and uses thereof
WO2023192648A1 (en) * 2022-03-31 2023-10-05 Puretech Lyt 100, Inc. Methods of treating interstitial lung diseases and other fibrotic-mediated pulmonary diseases and disorders with deupirfenidone
WO2024138185A1 (en) * 2022-12-23 2024-06-27 Bristol-Myers Squibb Company Lpa1 antagonists for treating interstitial lung disease

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6762180B1 (en) 1999-10-13 2004-07-13 Boehringer Ingelheim Pharma Kg Substituted indolines which inhibit receptor tyrosine kinases
DE10233500A1 (de) 2002-07-24 2004-02-19 Boehringer Ingelheim Pharma Gmbh & Co. Kg 3-Z-[1-(4-(N-((4-Methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylen]-6-methoxycarbonyl-2-indolinon-Monoethansulfonat und dessen Verwendung als Arzneimittel
US20040204458A1 (en) 2002-08-16 2004-10-14 Boehringer Ingelheim Pharma Gmbh & Co. Kg Use of Lck inhibitors for treatment of immunologic diseases
PE20060777A1 (es) 2004-12-24 2006-10-06 Boehringer Ingelheim Int Derivados de indolinona para el tratamiento o la prevencion de enfermedades fibroticas
NZ591443A (en) 2005-09-22 2013-04-26 Intermune Inc Granule formation of pirfenidone and pharmaceutically acceptable excipients
DK2124945T3 (da) 2006-12-18 2011-08-01 Intermune Inc Fremgangsmåde til at give pirfenidonterapi til en patient
US20170065529A1 (en) 2015-09-09 2017-03-09 Boehringer Ingelheim International Gmbh Pharmaceutical dosage form for immediate release of an indolinone derivative
US20110301177A1 (en) 2008-06-06 2011-12-08 Boehringer Ingelheim International Gmbh Capsule pharmaceutical dosage form comprising a suspension formulation of an indolinone derivative
US7566729B1 (en) 2008-11-10 2009-07-28 Intermune, Inc. Modifying pirfenidone treatment for patients with atypical liver function
US7635707B1 (en) 2008-11-10 2009-12-22 Intermune, Inc. Pirfenidone treatment for patients with atypical liver function
GB2470833B (en) 2009-06-03 2011-06-01 Amira Pharmaceuticals Inc Polycyclic antagonists of lysophosphatidic acid receptors
US7816383B1 (en) 2009-12-04 2010-10-19 Intermune, Inc. Methods of administering pirfenidone therapy
US8084475B2 (en) 2009-12-04 2011-12-27 Intermune, Inc. Pirfenidone therapy and inducers of cytochrome P450
PL2648726T3 (pl) 2010-12-07 2018-10-31 Amira Pharmaceuticals, Inc. Policykliczny antagonista lpa1 i jego zastosowania
US20150164874A1 (en) 2011-05-25 2015-06-18 Intermune, Inc. Pirfenidone and anti-fibrotic therapy in selected patients
WO2013025733A1 (en) * 2011-08-15 2013-02-21 Intermune, Inc. Lysophosphatidic acid receptor antagonists
CA2819967C (en) 2012-08-31 2016-03-22 Intermune, Inc. Use of pirfenidone concomitantly with ciprofloxacin
AR092742A1 (es) 2012-10-02 2015-04-29 Intermune Inc Piridinonas antifibroticas
CN106459042B (zh) 2014-04-02 2019-06-28 英特穆恩公司 抗纤维化吡啶酮类
JP2019523225A (ja) * 2016-06-01 2019-08-22 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ニンテダニブおよびピルフェニドンによる治療開始を決定するためのecmバイオマーカーの使用
HRP20230645T1 (hr) 2018-02-02 2023-09-29 Genentech, Inc. Farmaceutski spoj, njegove soli, njegove formulacije i postupci izrade i upotrebe istih
FI3802517T3 (fi) 2018-06-07 2023-03-23 Idorsia Pharmaceuticals Ltd Alkoksisubstituoituja pyridinyylijohdannaisia LPA1-reseptoriantagonisteina ja niiden käyttö fibroosin hoidossa
AR119162A1 (es) * 2019-06-18 2021-12-01 Idorsia Pharmaceuticals Ltd Derivados de piridin-3-ilo

Similar Documents

Publication Publication Date Title
JP2017528507A5 (es)
JP2021181493A5 (ja) クロモリンを含む粉末組成物
JP4643760B2 (ja) Dpp−iv阻害薬と他の糖尿病治療薬との併用又は組み合せからなる医薬
JP2017526716A5 (es)
JP2017528503A5 (es)
JP2020523335A5 (es)
JP2013543896A5 (es)
JP2014526501A5 (es)
JP2016512825A5 (es)
JP2014530900A5 (es)
RU2011121567A (ru) Изоиндолиновые соединения для применения при лечении рака
JP2016534063A5 (es)
JP2014502979A5 (es)
JP2019515884A5 (es)
JP2017505293A5 (es)
JP2018529779A5 (es)
JP2023076632A5 (es)
JP2016512517A5 (es)
JP2019536812A5 (es)
JP2008521934A5 (es)
JP2013526520A5 (es)
JP2011507879A5 (es)
JP2017522348A5 (es)
JPWO2021110805A5 (es)
JP2008520611A5 (es)